• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

婴儿血管瘤表达肿瘤坏死因子相关凋亡诱导配体(TRAIL)、TRAIL 受体、骨保护素和核因子кB 配体受体激活剂(RANKL)。

Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor кB ligand (RANKL).

机构信息

School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.

出版信息

Histopathology. 2011 Sep;59(3):397-406. doi: 10.1111/j.1365-2559.2011.03970.x.

DOI:10.1111/j.1365-2559.2011.03970.x
PMID:22034880
Abstract

AIMS

To investigate the expression of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and its receptors and decoy receptors, including osteoprotegerin (OPG) in infantile haemangioma (IH).

METHODS AND RESULTS

Immunostaining, Western blotting and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) were used on IH biopsies and haemangioma explant-derived cells (HaemEDCs). TRAIL and its receptors and decoy receptors, including OPG, are expressed in proliferating IH tissues and in HaemEDCs. Cells forming the endothelium of immature capillaries of proliferating IHs express abundant OPG and show punctate von Willebrand Factor (vWF) staining. As the cells mature and assume the characteristic of endothelial cells they increase expression of vWF, but lose expression of OPG. The endothelium of IH shows minimal expression of receptor activator for nuclear factor кB ligand (RANKL) compared with a small population of RANKL-positive cells located within the interstitium between microvessels. Proliferating HaemEDCs express significantly higher levels of OPG and decoy receptor 2 than the matched tissue samples. Increased OPG expression is detected in the extracellular matrix and in the conditioned medium of HaemEDCs.

CONCLUSIONS

Our data suggest that OPG through the TRAIL pathway, but not the RANKL pathway, plays a role in regulating anti-apoptosis during the development of IH.

摘要

目的

研究肿瘤坏死因子相关凋亡诱导配体(TRAIL)及其受体和诱饵受体,包括骨保护素(OPG)在婴儿血管瘤(IH)中的表达。

方法和结果

采用免疫组化、Western blot 和定量逆转录聚合酶链反应(qRT-PCR)检测 IH 活检组织和血管瘤衍生细胞(HaemEDCs)中 TRAIL 及其受体和诱饵受体,包括 OPG 的表达。TRAIL 及其受体和诱饵受体,包括 OPG,在增殖性 IH 组织和 HaemEDCs 中表达。形成增殖性 IH 不成熟毛细血管内皮的细胞表达丰富的 OPG,并显示点状 von Willebrand 因子(vWF)染色。随着细胞成熟并表现出内皮细胞的特征,它们增加 vWF 的表达,但失去 OPG 的表达。与位于微血管之间间质内的一小部分 RANKL 阳性细胞相比,IH 的内皮细胞表达的核因子кB 配体受体激活剂(RANKL)很少。增殖的 HaemEDCs 表达的 OPG 和诱饵受体 2 明显高于匹配的组织样本。在 HaemEDCs 的细胞外基质和条件培养基中检测到 OPG 表达增加。

结论

我们的数据表明,OPG 通过 TRAIL 途径,而不是 RANKL 途径,在 IH 发育过程中调节抗凋亡作用。

相似文献

1
Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor кB ligand (RANKL).婴儿血管瘤表达肿瘤坏死因子相关凋亡诱导配体(TRAIL)、TRAIL 受体、骨保护素和核因子кB 配体受体激活剂(RANKL)。
Histopathology. 2011 Sep;59(3):397-406. doi: 10.1111/j.1365-2559.2011.03970.x.
2
Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.核因子κB受体激活剂配体(RANKL)和肿瘤坏死因子相关凋亡诱导配体(TRAIL)在乳腺癌中的表达及其与骨保护素、雌激素受体和临床病理变量的关系。
J Clin Pathol. 2006 Jul;59(7):716-20. doi: 10.1136/jcp.2005.030031. Epub 2006 Feb 17.
3
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours.人乳腺肿瘤中骨保护素(OPG)、肿瘤坏死因子相关凋亡诱导配体(TRAIL)和核因子κB受体激活剂配体(RANKL)的表达
J Clin Pathol. 2006 Jan;59(1):56-63. doi: 10.1136/jcp.2005.026534.
4
Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas.骨保护素(OPG)与肿瘤坏死因子相关凋亡诱导配体(TRAIL)结合:抑制成釉细胞瘤中TRAIL诱导的细胞凋亡。
Oral Oncol. 2006 Apr;42(4):415-20. doi: 10.1016/j.oraloncology.2005.09.009. Epub 2006 Jan 18.
5
Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis.人骨髓基质细胞可保护前列腺癌细胞免受TRAIL诱导的凋亡。
J Bone Miner Res. 2004 Oct;19(10):1712-21. doi: 10.1359/JBMR.040703. Epub 2004 Jul 7.
6
Osteoprotegerin is expressed in colon carcinoma cells.骨保护素在结肠癌细胞中表达。
Anticancer Res. 2005 Nov-Dec;25(6B):3809-16.
7
Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.骨保护素及核因子-κB受体激活因子配体(RANKL)在HCC70乳腺癌细胞中的表达以及促性腺激素释放激素处理对RANKL表达的影响
Gynecol Endocrinol. 2008 Jun;24(6):331-8. doi: 10.1080/09513590802095845.
8
Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.骨保护素是肿瘤坏死因子相关凋亡诱导配体/Apo2配体的可溶性诱饵受体,可作为人骨髓瘤细胞的旁分泌生存因子发挥作用。
Cancer Res. 2003 Mar 1;63(5):912-6.
9
Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis.地塞米松抑制乳腺癌细胞护骨素的产生并赋予其对 TRAIL 诱导的细胞凋亡的抗性。
J Cell Biochem. 2009 Sep 1;108(1):106-16. doi: 10.1002/jcb.22232.
10
Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function.骨保护素和核因子κB受体活化因子配体对血管生成和内皮细胞功能有不同的调节作用。
Angiogenesis. 2009;12(1):35-46. doi: 10.1007/s10456-008-9127-z. Epub 2008 Dec 23.

引用本文的文献

1
Global research trends of infantile hemangioma: A bibliometric and visualization analysis from 2000 to 2022.婴儿血管瘤的全球研究趋势:2000年至2022年的文献计量学与可视化分析
Heliyon. 2023 Oct 21;9(11):e21300. doi: 10.1016/j.heliyon.2023.e21300. eCollection 2023 Nov.
2
Expression of Cathepsins B, D, and G in Infantile Hemangioma.组织蛋白酶B、D和G在婴儿血管瘤中的表达
Front Surg. 2015 Jun 17;2:26. doi: 10.3389/fsurg.2015.00026. eCollection 2015.
3
Biology of infantile hemangioma.婴儿血管瘤的生物学特性
Front Surg. 2014 Sep 25;1:38. doi: 10.3389/fsurg.2014.00038. eCollection 2014.